Tempus AI Stock Price, News & Analysis

Tempus AI (NASDAQ: TEM) has launched Notetaker, an AI-powered clinical assistant designed to help psychiatrists generate progress notes. The tool, available through Tempus Hub, automatically records and transcribes patient sessions, creating clinical notes that integrate with electronic health records. Notetaker features real-time transcription with specialized psychiatric terminology recognition, automatic clinical note generation, and care gap notifications with pharmacogenomic insights.

The platform supports over 30 languages including English, Spanish, and Chinese, with automatic language switching capabilities. It complements Tempus' existing mental health solutions, including the Tempus nP pharmacogenomic test and PRO™ patient reported outcome solution. The HIPAA-compliant system offers adjustable settings for telehealth, in-person sessions, and dictation.

Tempus AI (NASDAQ: TEM) is expanding its TIME Network's support for phase I clinical trials through the newly formed TIME Precision Network. The network connects over 40 phase I-capable research centers, focusing on rapid trial activation and enrollment. Notable achievements include: activating the Taylor Cancer Research Center (TCRC) in approximately two weeks for the Nimbus 9216-101 study with first patient enrollment within a month, and successfully enrolling the first two patients for the Pathos P300-02-001 study at Nebraska Cancer Specialists and Oncology Consultants within weeks. The TIME Network, established in 2019, leverages data integration to match patients with trials efficiently, with sites activated within days or weeks. The initiative aims to expand clinical trial access to underrepresented patient groups through community hospitals across the U.S.

Tempus has published a validation study in the Journal of Molecular Diagnostics showcasing the effectiveness of its xF+ liquid biopsy assay. The study confirms that xF+ serves as a non-invasive method to detect actionable variants, identify biomarkers, and monitor disease progression.

Key highlights of the xF+ assay include:

• Coverage of 523 genes spanning ~1.8 Mb of the human genome
• Integration with Tempus multimodal database
• Demonstrated concordance with Tempus xF and xT assays for MSI status
• Proven accuracy, sensitivity, specificity, and precision

Originally launched in 2022, xF+ stands as one of the largest clinically available liquid biopsy panels for physicians. The validation process involved clinical samples, reference standards, synthetic cell lines, and healthy control samples.

Tempus AI (NASDAQ: TEM) has unveiled Tempus Loop, an innovative oncology-focused platform for target discovery and validation. The platform integrates real-world patient data (RWD), human-derived biological models, and CRISPR-screens with AI to accelerate pre-clinical therapeutic development.

Loop addresses a critical industry challenge where conventional approaches using cell lines or animal models often fail to reliably represent human tumors. The platform identifies patient subpopulations with similar clinical patterns and uses systems biological approaches to reveal novel target genes. It leverages patient-derived organoids (PDOs) for validation, ensuring closer reflection of patient attributes.

The platform has already demonstrated success, helping a large pharmaceutical company prioritize drug targets in patient subpopulations with unmet needs, validating targets within a year. According to Chief Scientific Officer Kate Sasser, PhD, this approach aims to improve the current 90% failure rate for preclinical assets becoming real-world medicines.

Tempus AI (NASDAQ: TEM) announced the acceptance of 18 abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The presentations include one oral and multiple poster sessions showcasing the company's AI-driven research in oncology.

Key research highlights include: 1) An oral presentation examining SF3B1 hotspot mutations in breast cancer, analyzing data from 420 patients; 2) A poster on NUTM1 structural variants, identifying 59 NUT carcinoma patients with an 81% NUTM1 fusion rate; 3) A study of 109 patients evaluating circulating tumor DNA as a biomarker for tyrosine kinase inhibitor therapy response; and 4) A collaborator-led presentation with T-knife Therapeutics on TCR-T therapy targeting PRAME-positive solid tumors.

Tempus AI (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 6, 2025. The earnings conference call will be held at 4:30 p.m. ET on the same day.

The presentation will feature CEO Eric Lefkofsky and CFO Jim Rogers. Investors can access the live audio webcast through Tempus' Investor Relations website's events page or join via phone using the conference ID 4680302 (Domestic: 800-715-9871, International: 646-307-1963).

Tempus AI (NASDAQ: TEM) has announced multi-year strategic collaborations with AstraZeneca and Pathos AI to develop the largest multimodal foundation model in oncology. The partnerships will focus on:

• Gathering biological and clinical insights
• Discovering novel drug targets
• Developing therapeutics for the oncology community

The agreements include $200 million in data licensing and model development fees to Tempus. The collaboration expands on Tempus' existing 2021 partnership with AstraZeneca, utilizing Tempus' AI-enabled platform and multimodal data repository to advance therapeutic programs in oncology globally. The foundation model will be built using Tempus' de-identified oncology data and will be shared among all three parties to enhance their respective patient care initiatives.

Tempus AI (NASDAQ: TEM) has announced the formation of its Advisory Board, comprising distinguished physicians from leading medical institutions across the United States. The board will provide strategic guidance on research, product development, and clinical utility of Tempus's AI-enabled platform for precision medicine.

Led by Dr. Ezra Cohen, Chief Medical Officer of Oncology at Tempus, the advisory board includes 13 renowned medical professionals specializing in various oncology fields. Notable members include directors and professors from prestigious institutions such as Ohio State University Medical Center, UCLA, MD Anderson Cancer Center, Mayo Clinic, and Vanderbilt-Ingram Cancer Center.

The advisory board's primary focus will be maintaining high standards and ensuring the company's strategy remains grounded in expert knowledge, supporting Tempus's mission of advancing precision medicine and patient care through AI technology.

Illumina (NASDAQ: ILMN) and Tempus AI (NASDAQ: TEM) have announced a strategic collaboration to accelerate the clinical adoption of next-generation sequencing tests through AI-driven innovation. The partnership aims to combine Illumina's AI technologies with Tempus's multimodal data platform to enhance genomic algorithms and expand molecular profiling across various disease categories.

The collaboration focuses on developing evidence to standardize comprehensive genomic profiling and molecular testing beyond cancer, extending to cardiology, neurology, and immunology. This builds upon the companies' existing partnership in developing tools and assays for testing needs from preemptive screening through therapy selection.

The initiative addresses the current gap where patients often miss precision medicine benefits due to non-standardized molecular profiling across disease areas and regions. The partnership will leverage data analytics and sequencing technologies to improve patient outcomes and advance precision medicine research.